Biocept, Inc. (Nasdaq:BIOC), a molecular diagnostics company
commercializing and developing liquid biopsies to improve the diagnosis
and treatment of cancer, continues to build evidence of the clinical
utility of its liquid biopsy offerings with an abstract at the 2015
Annual American Society of Clinical Oncology Meeting in Chicago starting
on May 29, 2015.
Biocept offers a sensitive and quantitative blood-based method for the
detection and monitoring of clinically actionable cancer biomarkers in
order to help doctors make treatment decisions based on genomic
information gained from the tumor material. The Company is engaged in
multiple clinical studies designed to demonstrate the utility of its
liquid biopsy diagnostic to detect a patient’s biomarker status and for
the assessment of treatment response over time.
The abstract demonstrates the clinical utility of a liquid biopsy using
Biocept’s technology, not only for a patient where there is insufficient
tissue from a biopsy, but also in order to better represent a patient’s
biomarker status by avoiding challenges associated with tissue
heterogeneity, all accomplished with a simple blood draw.
"By providing oncologists such as myself with genomic testing results
performed on a simple blood test, we are able to stratify patients based
on biomarker status in real-time, which has the potential to drastically
change how patients with solid cancers such as non-small cell lung
cancers (NSCLC) are monitored," stated Dr. Lyudmila Bazhenova, MD,
Associate Clinical Professor of Medicine at University of California,
San Diego Moores Cancer Center.
"The ease of real-time monitoring and early identification
of the emergence of resistance reduces the time to make a treatment
change, which in a setting of metastatic cancer, is crucial.
Additionally, the health economic benefit of obtaining actionable
biomarker status from a simple blood draw in lieu of a surgical
procedure is an added advantage to our health care system,” stated Veena
Singh, MD, Sr. VP and Medical Director at Biocept.
The abstract also highlights the Biocept platform’s ability to provide
subsequent serial monitoring of biomarker status after therapy to
monitor clinical response as well as progression. “This is an important
feature of the platform,” noted Dr. Singh. “Emerging therapies such as
rociletinib and AZD9291 are in advanced clinical development and have
been shown to benefit patients with T790M mutations, another biomarker
associated with lung cancer. As the next-generation of therapies come to
market, it will be important that clinicians have a method to perform
serial monitoring on patients in order to understand when they are
candidates for these therapies. At Biocept, we offer a test to detect
these biomarkers.”
About Biocept
Biocept, Inc. is a commercial-stage molecular diagnostics company that
utilizes a proprietary technology platform and a standard blood sample
to provide physicians with important prognostic and predictive
information to enhance individual treatment of patients with cancer.
Biocept’s technology platform captures and analyzes circulating tumor
DNA, both in CTCs and in plasma (ctDNA). Biocept currently offers
OncoCEE-GA™ for gastric cancer, OncoCEE-BR™ for breast cancer and
OncoCEE-LU™ for non-small cell lung cancer, and plans to introduce
CLIA-validated tests for colorectal, prostate and other solid tumors in
the near term.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations reflected
in the forward-looking statements and the assumptions upon which they
are based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect," "anticipate,"
"estimate," "believe," "intend," or "project" or the negative of these
words or other variations on these words or comparable terminology. To
the extent that statements in this release are not strictly historical,
including without limitation statements as to improvement of outcomes,
our impact on diagnostic strategies and planned future offerings, such
statements are forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. The
reader is cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous risk factors as
set forth in our Securities and Exchange Commission (SEC) filings. The
effects of such risks and uncertainties could cause actual results to
differ materially from the forward-looking statements contained in this
release. We do not plan to update any such forward-looking statements
and expressly disclaim any duty to update the information contained in
this press release except as required by law. Readers are advised to
review our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20150528005339r1&sid=ntxv4&distro=nx&lang=en)
View source version on businesswire.com: http://www.businesswire.com/news/home/20150528005339/en/
Copyright Business Wire 2015